Clinical Trial Update: DDP ip Combined With AG in PDAC With Peritoneal Metastasis [Phase 2]

View source ↗

Summary

This is a completed Phase 2 trial evaluating intraperitoneal cisplatin (DDP ip) combined with AG in pancreatic ductal adenocarcinoma with peritoneal metastasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• AG regimen (AG)
• cisplatin (intraperitoneal) (cisplatin)

Snippet

Sponsor: Fudan University | Conditions: Pancreatic Neoplasm | Phase 2 | Status: COMPLETED